Kidney cancer ranks among the ten most common malignancies worldwide and is growing rapidly in India since last two decades. Unlike many other cancers that indicate with early warning signs, renal malignancies are generally asymptomatic in their initial stages. A significant proportion of these cases are detected incidentally during laboratory or clinical evaluation for unrelated conditions, by which time the tumour may have been growing silently for months or even years.
In India, kidney cancer diagnosis is increasing in frequency, particularly among patients between 50 and 70 years of age. Urban centres such as Ahmedabad, Mumbai, Kolkata, Surat, Jaipur and Hyderabad report rising caseloads, driven by a combination of aging demographics, lifestyle-related risk factors and improved diagnostic access that identifies tumours which would have gone undetected a decade ago.
Knowing what kidney cancer is, recognising the risk factors that contribute and knowing how modern pathology supports early detection are significantly critical steps. This guide covers the kidney cancer causes, the kidney cancer symptoms to watch for, staging, diagnostic pathways and the most reliable kidney cancer treatment options in a clinically grounded format designed for patients and families seeking trustworthy information.
What is Kidney Cancer?
Kidney cancer generally originates when cells in the kidney tissue begin to grow and divide in an uncontrolled manner, forming a tumour. The kidneys are two bean-shaped organs located behind the abdominal organs on either side of the human spine. The primary function of kidney includes filtering blood, removing waste products, regulating fluid and electrolyte balance and producing hormones that control blood pressure and red blood cell production.
When malignant cells develop within the kidney, they can disrupt these functions progressively, which is why a kidney function test is often part of the initial evaluation when abnormalities are suspected.
In the early stages, kidney cancer seldom produces noticeable symptoms. It is mostly discovered incidentally during diagnostic workups for unrelated conditions, a reality that makes awareness and knowledge of risk factors even more important.
Types of Kidneys Cancer?
All kidney tumours don’t behave in the same way. The types of kidney cancer are classified based on the origin cell, each with a distinct biological behaviour, prognosis and the response to the treatment.
- Renal Cell Carcinoma (RCC): This type accounts for approximately 85% of all kidney cancers in adults. Clear cell RCC is the most common subtype, followed by papillary RCC and chromophobe RCC. The clear cell variant is associated with mutations in the VHL gene, a finding that has shaped modern targeted therapy approaches.
- Transitional Cell Carcinoma (TCC): This cancer type arises from the cells lining the renal pelvis rather than the kidney tissue itself. This type accounts for roughly 5-10% of kidney cancers. This type shares its characteristics with bladder cancer and is often treated with similar protocols.
- Wilms Tumour (Nephroblastoma): A childhood kidney cancer, most diagnosed in children between 3 and 4 years of age. Distinct from adult kidney cancers in both biology and treatment approach, this type has high cure rates when detected early.
- Renal Sarcoma: This is a rare form that develops in the connective tissue of the kidney. This cancer accounts for less than 1% of all kidney malignancies.
Accurate subtype identification is clinically essential because treatment strategies differ significantly between them. Molecular and genetic profiling through advanced pathology testing has become a critical component of this classification process.
Kidney Cancer Causes and Risk Factors?
The precise kidney cancer causes are not fully established for every case. However, decades of epidemiological and molecular research have identified several factors that measurably increase the risk manifolds.
Established Risk Factors of Kidney Cancer
- Smoking: Tobacco use roughly doubles the risk of developing renal cell carcinoma. The risk increases with the duration and intensity of smoking and decreases gradually after cessation.
- Obesity: Excess body weight, particularly central adiposity, is strongly associated with kidney cancer. Hormonal changes related to obesity, including elevated insulin and insulin-like growth factor levels, are thought to promote renal cell proliferation.
- Chronic hypertension: Sustained high blood pressure has been independently linked to kidney cancer risk. Whether the association is driven by hypertension itself or by the medications used to treat it remains an area of active investigation.
- Chronic kidney disease and dialysis: Patients on long-term haemodialysis develop cystic changes in the kidneys that carry an elevated malignancy risk over time.
- Occupational exposure: Prolonged contact with certain industrial chemicals, including trichloroethylene, cadmium and asbestos, has been associated with higher incidence rates in occupational health studies.
- Family history and hereditary syndromes: Conditions such as von Hippel-Lindau (VHL) disease, hereditary papillary RCC, Birt-Hogg-Dubé syndrome and hereditary leiomyomatosis significantly increase lifetime risk. These syndromes often involve germline mutations that can be detected through genetic testing.
The Role of Genetic Testing in Risk Assessment
For families with a history of kidney cancer or patients diagnosed at an unusually young age, genetic profiling can identify hereditary risk factors that inform both surveillance and treatment decisions. The following molecular tests are available at Unipath Speciality Laboratory:
- NGS Cancer Hot Spot V2 Panel (50 Gene Mutations): Screens for somatic mutations across 50 cancer-related genes, including those implicated in renal cell carcinoma. Useful for both diagnostic confirmation and therapy selection.
- NGS Hereditary Cancer Panel (Germline): Identifies inherited germline mutations across cancer predisposition genes. Particularly relevant for patients with familial kidney cancer or hereditary syndromes such as VHL disease.
- FISH MET Gene Amplification: Detects amplification of the MET gene, a biomarker relevant in papillary renal cell carcinoma and an emerging target for personalised therapy approaches.
All molecular and genetic tests at Unipath are processed under NABL-accredited protocols, ensuring the level of accuracy required for clinical decision-making in oncology. While diagnosis is done in Ahmedabad, the samples can be collected from across Ahmedabad, Vadodara, Jamnagar, Surat, Mumbai, Kolkata, Jaipur, Siliguri, Indore, Srinagar and Hyderabad.
Kidney Cancer Symptoms and Signs to Watch?
Most early-stage kidney cancers are notoriously asymptomatic. The kidney cancer symptoms that eventually appear tend to manifest only after the tumour has grown large enough to affect surrounding structures or has begun to spread.
Common Symptoms of Kidney Cancer
- Blood in the urine (haematuria) — may be visible or detected only through microscopic urinalysis
- Persistent pain in the lower back or flank, typically on one side, unrelated to injury
- A palpable mass or swelling in the abdomen or flank region
- Unexplained weight loss and persistent fatigue
- Intermittent fever not attributable to infection
- Anaemia detected incidentally on routine blood work
- Elevated blood pressure that develops suddenly or worsens without clear cause
Because kidney cancer symptoms often overlap with those of several benign conditions, a combination of findings is more clinically significant than any single symptom. In particular, haematuria accompanied by flank pain or unexplained weight loss warrants prompt clinical investigation, including blood work and urine analysis.
Stages of Kidney Cancer
The kidney cancer stages follow the TNM classification system (Tumour, Node, and Metastasis) and determine both treatment approach and prognosis.
- Stage I: Tumour is confined to the kidney and measures 7 cm or less. Five-year survival rates are high, often exceeding 90%. The tumour has not spread to lymph nodes or distant sites.
- Stage II: Tumour is still confined to the kidney but exceeds 7 cm. No lymph node involvement or metastasis. Prognosis remains favourable with appropriate surgical management.
- Stage III: Tumour has extended beyond the kidney into surrounding tissues, major veins or nearby lymph nodes. Treatment becomes more complex, often involving a combination of surgery and systemic therapy.
- Stage IV: Cancer has spread to distant organs — most commonly the lungs, bones, liver or brain. Treatment at this stage focuses on controlling disease progression and maintaining quality of life through systemic therapies, including immunotherapy and targeted agents.
Staging accuracy depends heavily on the quality of pathological analysis. Tissue biopsy, molecular profiling and biomarker evaluation through a NABL-accredited laboratory are essential components of determining the correct stage and the relevant treatment.
Kidney Cancer Diagnosis: How Is It Confirmed?
Kidney cancer diagnosis is a multi-step process that combines clinical assessment, laboratory analysis and tissue-level pathology to arrive at a definitive conclusion.
- Blood and Urine Tests: Complete blood count (CBC), renal function tests (creatinine, BUN, electrolytes), liver function tests and urinalysis form the initial laboratory workup. Haematuria on urinalysis and anaemia on CBC are common initial findings.
- Complete blood count (CBC), renal function tests (creatinine, BUN, electrolytes), liver function tests and urinalysis form the initial laboratory workup. Haematuria on urinalysis and anaemia on CBC are common initial findings.
- Biopsy and Histopathology: Tissue obtained through renal biopsy is examined by pathologists to determine tumour type, grade and molecular characteristics. This remains the gold standard for definitive kidney cancer diagnosis.
- Molecular and Genetic Profiling: Advanced tests such as the NGS Cancer Hot Spot V2 Panel, NGS Hereditary Cancer Panel and FISH MET Gene Amplification provide actionable data on tumour biology, hereditary risk and targeted therapy eligibility.
At Unipath Speciality Laboratory, oncology pathology services are structured to deliver accurate, timely results that clinicians need for staging, treatment planning and ongoing monitoring.
Kidney Cancer Treatment: Current Approaches?
Kidney cancer treatment depends on the stage at diagnosis, the tumour subtype, the patient's overall health status and increasingly on the molecular profile of the cancer itself. Modern kidney cancer treatment is highly individualised, and the right kidney cancer treatment plan is built around accurate staging and pathology.
Surgical Options
- Partial nephrectomy: Removal of the tumour along with a margin of healthy tissue, preserving the remainder of the kidney. Preferred for Stage I and selected Stage II tumours.
- Radical nephrectomy: Complete removal of the affected kidney, surrounding tissue and sometimes adjacent lymph nodes. Standard for larger or locally advanced tumours.
Systemic Therapies
- Targeted therapy: Drugs such as sunitinib, pazopanib, cabozantinib and axitinib target specific molecular pathways involved in tumour growth, particularly the VEGF and mTOR pathways.
- Immunotherapy: Checkpoint inhibitors such as nivolumab and pembrolizumab have transformed outcomes in advanced renal cell carcinoma. Combination immunotherapy regimens are now standard first-line treatment for metastatic disease.
- Ablative procedures: Cryoablation and radiofrequency ablation may be considered for small tumours in patients who are not candidates for surgery.
The Role of Pathology in Treatment Selection
The era of one-size-fits-all kidney cancer treatment has ended. Molecular profiling through next-generation sequencing (NGS) panels and biomarker assays now directly informs which therapy a patient receives. Whether a tumour responds to a VEGF inhibitor, an mTOR inhibitor or an immune checkpoint agent depends on its genetic and molecular characteristics information that only high-quality pathology testing can provide.
Unipath Diagnostic Services: Serviceable Cities
Ahmedabad • Surat • Vadodara • Kolkata • Jaipur • Mumbai • Siliguri • Jamnagar
For test bookings and inquiries: Contact Unipath
Disclaimer
Unipath does not represent or warrant that the content or information provided through our blog is accurate, complete, or current, nor that our blog content will be uninterrupted or error-free. We do not guarantee that any defects in our blog content will be corrected or that our server or the server hosting them is free of viruses or other harmful components. Unipath makes no warranties or representations regarding the use of materials in our blog content concerning their correctness, accuracy, adequacy, usefulness, timeliness, reliability, or otherwise, to the fullest extent permitted by applicable law. Information available via our platform and blog content may reference products, programmes, or services not available in your region. You understand and acknowledge that your sole and exclusive remedy for any defect in or dissatisfaction with our blog content is to cease using it.
References & Citations
Mayo Clinic – Kidney Cancer: Symptoms and Causes
Mayo Clinic – Kidney Cancer: Diagnosis and Treatment
National Cancer Institute – Renal Cell Cancer Treatment (PDQ)
National Cancer Institute – Advances in Kidney Cancer Research
American Cancer Society – Kidney Cancer Overview
World Health Organization – Cancer: Key Facts